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Abstract
Invasive fungal infections have become a serious problem in the critically ill. One of the main reasons is the develop-
ment of an immunocompromised condition. The most frequently found pathogens are Candida species. In order to 
provide adequate treatment, understanding this potentially life-threatening infection is mandatory. The aim of this 
summary is to view Candida infections from a different perspective and to give an overview on epidemiology, the 
range of pathophysiology from colonization to the invasive infections, and its impact on mortality. New therapeutic 
options will also be discussed and how these relate to current guidelines. Finally, the key issue of the choice of anti-
fungal agents will be evaluated.
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 Introduction
The incidence of invasive mycoses has increased five 
fold in the past decade caused by two underlying fac-
tors. Firstly, more and more patients with impaired im-
munity are being treated and secondly, prolonged stay 
in hospitals facilitates the development of invasive my-
coses [1,2]. Although means of diagnosing mycoses has 
improved, early specific diagnosis still remains a chal-
lenge [3]. The high mortality and morbidity related to 
invasive fungal infections renders early adequate source 
a pivotal role [4,5]. The problem stems from the fact that 
clinicians often fail to consider the possible outcomes of 
these infections, and also that the etiology of the infec-
tion is not always adequately established. The aim of this 
review is to give guidance on how to develop a some-
what different way of thinking about both diagnostics 
and therapy. Accordingly, a brief review of the decision 
algorithms necessary to establish diagnosis and starting 
antifungal therapy will be preented, followed by guid-
ance on choosing appropriate antifungal agents.
 Epidemiology, Incidence, Mortality
There are 100,000 known fungus species of which 400 
are important from a medical point of view. Less than 
fifty of the species are human pathogens. Most of the in-
fections are nosocomial and account for approximately 
15% of healthcare related infections. Candida species 
are responsible for the vaste majority of fungal infec-
tions (70-90%), followed by the Aspergillus species (10-
20%) [6]. EPIC II, (2007) was a one-day, prospective 
point prevalence study which highlighted Candidae as 
the third most common pathogen, responsible for 17% 
of all the infections [7].  A Swiss study confirmed that 
one-third of candidaemia occurs in intensive care units 
(ICU) [8]. Candida infections occur five to ten times 
more often (2-6.7 in 1000 admitted patients) in ICUs 
than on medical or surgical wards. In the USA it is the 
third and fourth most common pathogen isolated from 
blood cultures and accounts for 8-10% of bloodstream 
infections. In Europe it is the sixth to tenth most com-
monly identified pathogen and responsible for 2-3% of 
bloodstream infections [9]. According to current data, 
mortality rate of invasive Candida infections is con-
sidered high. Recent studies indicate it varies between 
40-60% [10-12] and within certain conditions mortal-
ity can reach 100% [5]. Epidemiology of candidae has 
changed in the past 20 years. While earlier candida 
albicans was the dominant pathogen and caused two-
thirds of the infections, currently increasing number of 
non-albicans species can be noticed and are responsi-
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ble for almost 50% of the infections. These include C. 
glabrata, C. krusei, C. tropicalis and C. parapsilosis [13]. 
There are several other factors, which can affect the oc-
currence of different candida species. While Candida 
glabrata is more common among elderly people, Can-
dida parapsilosis is more common in Australia, South-
America and Southern Europe than in North-America 
or Northern Europe [13]. Characteristics of the differ-
ent Candida species are shown in Table 1 [14].
 Pathomechanism of invasive infec-
tions, endangered patients and risk 
factors
Since different candida species are part of the normal 
skin and mucous membrane flora, including orophar-
yngs, vagina and colon, colonization can occur already 
in the newborns during the birth process. Coloniza-
tion is not harmful among healthy subjects, however 
candida species can overgrow the normal flora through 
changes in the microbiom associated with among oth-
ers, antibiotic therapy, burn injury, neutropenia and 
diabetes mellitus, and additionaly certain predispos-
ing factors such as weak natural immunity, impaired 
cellular immunity, diabetes mellitus, and pregnancy. 
These factors can predispose to an invasive candida in-
fections. Different impacts on deep tissues can lead to 
micro-invasion due to barrier damage, and a possible 
source of candidaemia. Although this does not nec-
essarily progress in all cases to severe sepsis or septic 
shock, it can cause dissemination of the mycoses initi-
ating endophtalmitis, hepatosplenic, CNS, infective en-
docarditis or abscesses in different organs and tissues, 
and subsequently the establishment of severe sepsis.
An important clinical issue is to identify which pa-
tients are more susceptible to invasive candida infec-
tion. The most susceptible patients are those with im-
paried immunity, but several other medical conditions 
should be taken into account. These are summarised in 
Table 2 and 3.
Table 1. Characteristics of common non-albicans species
Species Characteristics
C. glabrata
Most common in elderly patients
Most common in malignancies
Geographic variation
Associated to the use of specific  
antibiotics, (piperacillin/tazobactam, 
vancomycin)
Common in patients under TPN and  
with CVC
Isolation system
Solid organ transplantation
Fluconazole exposure
C. parapsilosis
Nosocomial outbreaks
Formation of biofilms in CVC
Implanted devices
TPN
Less susceptible to echinocandins
The second most common isolated  
strain in children
C. tropicalis
Haematological malignancies
Neutropenia
C. krusei
Use of piperacillin/tazobactam, vanco-
mycin
Innate resistance to fluconazole
Haematological malignancies
Neutropenia
Recent gastrointestinal surgery
Fluconazole exposure
C. guiillermondi
Less susceptible to echinocandins
Less susceptible to fluconazole
Intravascular catheters
The table was imported from Paramythiotou E et al: Invasive Fungal Infections in the ICU: How to 
Approach, How to Treat [14], CVC = Central venous catheters, TPN = Total Parenteral Nutrition
Table 2. Endangered patients who are more susceptible 
to Candida infection
Impaired immunity Other medical conditions
Oncology Hollow organ perforation
Haemato-oncology Great abdominal surgery
Febrile neutropenia Urologic intervention with parallel candiduria
Neutropenia Polytrauma
HIV, AIDS Malnutrition
Immunosuppressive 
therapy Severe pancreatitis
Burn injury, where more 
than 50% of body surface 
is affected
ICU
Table 3. Risk factors in terms of Candida infection
High risk Non-specific risk
Multiple colonization Elderly age>65 years
Broad spectrum AB therapy Diabetes mellitus
TPN Renal failure
Dialysis Surgical intervention
APACHE II > 20 points Foley catheter
CVC Catheters inserted to ves-sels
Candiduria> 105cfu/ml Long ICU stay> 7 days
Multiple transfusion
CVC = Central venous catheters, TPN = Total Parenteral Nutrition
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 From colonisation to infection
Candida colonisation and infection are two closely 
related consecutive events which can occur follow-
ing illness. On admission to an ICU only 5-15% of 
the patients were reported to have candida colonisa-
tion, however this number increases to 50-80% during 
their stay in ICU. Only 5-30% of these patients devel-
oped an invasive candida infection [16]. Multifocal 
colonisation is common among ICU patients, mainly 
among those who have spent more than seven days 
on the ICU. The most commonly loci are the stomach 
(45.6%), oropharyngeal samples (34.3%), the trachea 
(23.4%), perirectal region (21.2%) and the urinary tract 
(18.7%). Recent studies show that the relative risk of 
invasive candidiasis was significantly higher in those 
patients whose faecal samples (7.5% vs. 3.2%, p=0.019) 
or urine samples (9.2% vs. 5.2%, p=0.032) were posi-
tive. Multifocal colonisation was found to be an inde-
pendent risk factor of invasive candidiasis. Pursuant to 
these results patients should be screened (faeces, urine, 
tracheal aspirate) twice a week enabeling the clinicians 
to identify patients at high risk of invasive candida in-
fection. Samples taken from other locations such as the 
stomach, skin, or pharynx, should also be taken into 
account [17,18]. Colonization can be low or high. The 
latter occurs if at least three samples are positive on two 
or more consecutive occasions [19].
Invasive candidiasis is a collective term which in-
cludes several indicators.
•	 Primary candidaemia is said to exist if one or 
more blood cultures taken from peripheral ve-
nous boold are positive for the fungus.
•	 Intra-abdominal candidiasis is said to exist if can-
dida is detected in peritoneal fluid obtained by di-
rect punction or from an intra-operative sample, 
or from a sample taken through an intra-abdom-
inal drain, inserted within the past 24 hours, or 
when a direct microscopic examination confirms 
fungal yarns.
•	 A mixed form candidiasis can consist of the ele-
ments constituting primer and intra-abdominal 
candidiasis. This group includes one-third of the 
patients. 
Most cases of invasive candidiasis occur between 
five to twelve days in an ICU. It is essential to differen-
tiate between catheter-related candidaemia and primer 
or intra-abdominal candidiasis-related candidaemia, 
since the latter has lower morbidity and mortality. Di-
agnosis of this can be established if the catheter sample 
and the peripheral blood sample confirms the same 
candida species. Rare manifestations of invasive can-
didiases exist i.e. endophtalmitis, endocarditis, men-
ingitis, pleural, bone and joint or hepatosplenic can-
didiasis. According to recent knowledge, colonisation 
of the GI tract (endogene path) has a prominent role 
in development of primary candidiasis while cases of 
catheter-related candida infections occur through the 
exogene path and are in relation with colonisation of 
the patient’s skin and of the healthcare workers’ hands 
[16].
Invasive candidiases can be separated into three 
groups: proven, probable or possible. Differentiation is 
based on cultures, biomarkers, clinical picture and the 
patient’s individual risk factors [16,20,21]. Infection 
is confirmed if proliferous fungal presence is proven 
from blood or infected tissue samples and microbio-
logic examination identify candida species in obtained 
samples. Infection is proven if both histology and mi-
crobiology identify proliferous fungal presence from 
blood or infected tissue samples. Infection is probable 
if a compromised patient who has been in the ICU for a 
prolonged period has heavily colonised severe sepsis or 
septic shock and positive for mannan, 1-3 beta-d-glu-
can, a known serum biomarker for candidemia. Infec-
tion is possible if an endangered patient who has been 
in an ICU for a prolonged period has heavily colonised 
severe sepsis or septic shock but negative biomarkers.
 Diagnostics
Numerous options are available for diagnosis, however 
none is perfect in itself. These include different scoring 
systems to assess risk, and highly sophisticated labo-
ratory measures to identify the pathogen. These must 
be combined, as systemic candidiasis is often accom-
panied with no candidemia, thus risk adapted empiric 
antifungal therapies play a  crucial role in treating inva-
sive candidiases [22,23].
Risk scores and prediction rules
Colonisation index
Colonisation and its degree has a crucial role in the 
development of invasive candida infection. In a study 
by Pitett et al [19], 29 severely colonised patients were 
investigated, of whom eleven had documented invasive 
candidiasis. The colonisation index was 0.47 in patients 
with no infection and 0.7 in patients with infection 
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(p<0.01). The cut-off value of colonisation index was 
defined as >0.5 which predicted the presence of inva-
sivity six days earlier than microbiologic cultures. This 
was confirmed by several subsequent studies [15,24-
26]. The negative predictive value of colonisation index 
is 100%, its positive predictive value is 66% [27], with a 
sensitivity of 64% and a specificity of 69.7% [25].
According to this, the dynamics and degree of colo-
nisation can be established through periodical screen-
ing of samples taken from the nose, throat, armpit, loin, 
submammal region, stomach, faeces, trachea aspirate 
and urine. It is advisable to perform screening among 
endangered patients or patients with risk factors, once 
or twice a week. Colonisation index can be calculated 
from the number of samples taken from non-sterile re-
gions idivided by the total number of samples. If the 
colonisation index exceeds the cut-off value (>0.5) 
consideration should be given to commensing  empiric 
antifungal therapy.
Candida score
The “Candida Score” [León et al, 2006] is an upgraded 
version of the Colonisation Index [28], based on a pro-
spective cohort study enrolling 1699 patients, out of 
which 97 (6%) had invasive candidiasis. The results of 
this study indicated that surgery [odd ratio (OR): 2.71; 
95% confidence interval (Cl): 1.45-5.06], multifocal 
colonisation (OR: 3.04; 95% CI: 1.45-6.39) and severe 
sepsis (OR: 7.68; 95% CI: 4.14-14.22) are predictors of 
invasive candidiasis. One point was allocated for each 
of these predictive factors in the candida score (except 
for severe sepsis, to which 2 points were allocated). A 
Candida score higher that 2,5 points has a sensitiv-
ity of 81%, a specificity of 74%, a negative predictive 
value of 98% and a positive predictive value of 16% for 
predicting invasive candidiasis. Its clinical adaptability 
was confirmed by several studies [25,29,30]. However, 
there are no prospective clinical studies examining the 
applicability of Candida Score as a guideline to start 
empiric antifungal therapy.
Ostrosky-Zeichner formula
This prediction formula was meant to identify patients 
who require antifungal profilaxis when in an ICU. In 
a study undertaken in a  surgical ICU [31], the inci-
dence of invasive candidiasis was found to be higher 
among those patients who spent four or more days in 
the ICU, had diabetes mellitus, required acute haemo-
dialysis, total parenteral nutrition or broad spectrum 
antibiotic therapy, compared to those who did not 
belong to any of the aformentioned groups. The inci-
dence of invasive candida infection in the two groups 
was 16.6% compared to 5.5% (p=0.001). Seventy eight 
% of these patients who later developed  candidaemia 
or invasive candidiasis were identified by this method. 
Several further investigations reported similar results 
(Table 4).
Non-culture-based methods
Culture-based diagnostic methods have a low sensitiv-
ity of approximately 50% [34], become positive rela-
tively late [35] and they are inadequate for diagnosing 
deep-seated candidiasis. Moreover, histopathologic 
methods, body fluid punctures and tissue biopsies are 
invasive and often clinically contraindicated, making 
them unavailable in everyday practice [15]. Therefore 
it is necessary to develop specific diagnostic methods 
with high sensitivity, which are applicable for quick 
recognition of invasive candida infections. These in-
clude cellular wall components, antigenes, antibodies 
and methods to identify circulating fungal DNA.
Table 4. Summary of predictive (Ostrosky-Zeichner) formulas
Population, invasive  
Candidiasis
Risk-based prediction model
Accuracy of  
prediction
2890 patients [88 (3%) 
with proven or probable 
IC] staying ≥4 days in nine 
US/Brazilian ICUs
Predictive rule – both systemic antibiotics and central venous catheter 
(day 1–3 of ICU stay); plus two of total parenteral nutrition (day 1–3 of 
ICU stay), dialysis (day 1–3 of ICU stay), major surgery (day –7 to 0 of 
ICU stay), pancreatitis (day –7 to 0 of ICU stay), steroids (day –7 to 3 of 
ICU stay), other immunosuppressive agents (day –7 to 0 of ICU stay)
Captured 34% of IC
Sensitivity=34%
Specificity=90%
PPV=10%
NPV=97%
97 ICU patients [22 (4%) 
with proven or probable 
IC] staying ≥4 days in six 
US ICUs
Predictive rule: all of: mechanical ventilation, broad-spectrum antibi-
otics and central venous catheter (day 1–3 of ICU stay); plus one of: 
total parenteral nutrition (day 1–3 of ICU stay), dialysis (day 1–3 of ICU 
stay), major surgery (day –7 to 0 of ICU stay), pancreatitis (day –7 to 0 
of ICU stay), steroids (day –7 to 3), other immunosuppressive agents 
(day –7 to 0 of ICU stay)
Captured 90% of IC
Sensitivity=90%
Specificity=48%
PPV=6%
NPV=99%
ICU: intensive care unit, PPV: positive predictive value, NPV: negative predictive value.
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(1,3)-b-D-Glucan
Detection of 1,3-b-D-Glucan (BDG) from the blood-
stream was first published by Obayashi et al. in 1995 
[36]. Subsequent investigations proved that BDG is an 
early biomarker of fungal infections [37-39] (except for 
zygomycetes and cryptococcoses which fungi’s cellular 
walls do not contain BDG). Different multicenter studies 
have also confirmed that a cut-off value of 80 pg/ml can 
detect and verify invasive candida infection with good 
sensitivity and specificity. The test had lower sensitiv-
ity and specificity in cases of candida parapsilosis [39]. 
Nevertheless, it gave positive results ten  days before the 
establishment of a clinical diagnosis of fungal infctions. 
It seems, that BDG is an adequate indicator of fungal 
infections hence a reliable biomarker for starting pre-
emptive anti-fungal therapy. Unfortunately the BDG test 
is relatively costly and needs properly equipped labora-
tories. The test can give  false positive results,  mainly 
in the first three days of being admitted to an ICU, and 
especially after surgical interventions, immunglobulin 
therapy, or in cases treated by certain antibiotics for bac-
terial infections, such as mainly Streptococcus Pneumoni-
ae. At the same time, it can cross-react with haemodialy-
sis membranes, gauze albumin or other blood products. 
The results might  also confirm invasive mould fungus 
infection [40]. Correlation between BDG levels, clini-
cal outcome and treatment response is evidence based 
[41]. Data about BDG kinetics are lacking, although 
the results of two studies [30,42] show that decreasing 
BDG serum levels refer to therapeutic success. If these 
results are confirmed by further clinical investigations, 
monitoring BDG levels could be used for assessing an-
tifungal therapy. The test is useful for measuring BDG 
levels in other body fluids such as cerebro-spinal [43], 
peritoneal fluid [44], or bronchoalveolar secretions [45]. 
However validation of these methods will be necessary 
in the future. The  European Organization for Research 
and Treatment of Cancer/Invasive Fungal Infections 
Cooperative Group and the National Institute of Allergy 
and Infectious Diseases Mycoses Study Group (EORTC/
MSG)], the European Society of Clinical Microbiol-
ogy and Infectious Diseases (ESCMDI) (candidemia: 
level evidence II), the Society of Critical Care Medicine 
(SCCM), European Society of Intensive Care Medicine 
(ESICM) (IC: Grade 2 B), and the Expert Panel (IAC: 
BII) all include BDG testing in their recommendations.
Mannan antigene and anti-mannan antibody
Mannan is a polysacharid component of candida cell 
wall, which circulates in the bloodstream in case of in-
vasive candidiases. Currently latex agglutination and 
enzyme immunoassay-based methods are in practice 
for mannan detection [46]. Combined examinations 
give the best results which means parallel detection of 
mannan antigene and anti-mannan antibody (Mn-an-
ti-Mn). According to a meta-analisys published in 2010 
containing 14 studies - 7 of which included non-neu-
tropenic critically ill patients, the sensitivity of mannan 
and anti-mannan investigations were 58% and 93% 
while their specificity were 59% and 83% separately.  In 
cases of Candida albicans, glabrata and tropicalis infec-
tions, when these investigations were combined, their 
sensitivity and specificity improved (83% and 86%) 
[47]. The European Society of Clinical Microbiology 
and Infectious Diseases (ESCMID) and the Surviving 
Sepsis Guidelines suggest the performance of a double 
test with C II evidence in these cases. The cause of the 
low quality of evidence is that most studies were retro-
spective and examined heterogeneous patient groups. 
To clarify the test’s role in everyday practice further 
investigations are necessary, examining homogeneous 
patient groups, defining the positive and negative pre-
dictive values and deciding wether simple or multiple 
positive results are needed to assert the diagnosis of in-
vasive candida infection.
Detection of candida nucleic acids by PCR
Fungal DNA detection by PCR technics is challeng-
ing. Human cell lysis leading to DNA “disengagement” 
can give false positive results. Exogene contamination 
from saprophytic or pathogen fungi can also lead to 
false positive results. Detailed discussion of the diffi-
culties of PCR techniques is beyond the scope of this 
summary. PCR techniques are capable of early detec-
tion of candidaemias and have been widely studied. In 
a review published by Khot in 2009 [48] the following 
observations were reported: 
•	 The method is appropriate for early detection of 
candidaemia.
•	 PCR is appropriate or detection of organic frag-
ments mainly if it aims a multicopy gene. 
•	  PCR detects non-viable organisms faster than 
cultures.
•	 Different platforms, blood samples and target 
genes are used during the test. 
In a later meta-analisys, 4894 patients of 54 studies 
were examined among who 963 had proven/probable or 
possible invasive candidiasis. Overall sensitivity and spec-
ificity of PCR in detection of invasive candidiasis were 
95% and 92% [49]. 
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In those cases when invasive candidiasis was possible, 
sensitivity of blood cultures and PCR were markedly dif-
ferent, 85% and 38%. PCR is certainly a significantly 
finer method and detects presence of invasive candidiasis 
earlier than blood cultures [50].
Direct molecular detection of Candidae from human 
samples is not a standard method and until it is not valid 
the place of PCR or other molecular methods in early 
detection of invasive candidiases remains uncertain.
Culture-based diagnostics
This group includes blood and other culture tests 
which are considered as the gold standard. Blood cul-
ture tests are appropriate and essential microbiologic 
methods of candidaemia detection. However blood 
cultures have also several pitfalls. If we assume candid-
iasis in our patients, a single sample of 40 ml of blood 
coud be insufficient because the sensitivity of the test 
is very low. According to the current recommendation 
60 ml of blood obtained by peripherial blood punction 
should be distributed in 3-3 different aerobic and an-
aerobic containers. This should be repeated daily and 
the containers should be incubated for a minimum of 
five days. According to current experience, the sensi-
tivity of blood cultures is around 50-70%. This sen-
sitivity may decrease in patients with neutropenia or 
during ongoing antifungal therapy [3]. In the case of 
suspected catheter related infections, samples should 
also be taken from the catheters to establish a source 
control. Although blood cultures are an essential part 
of the diagnostics they cannot be classified as early di-
agnostic strategies.
In cases of positive culture results for candida species, 
resistance tests should also be performed, and is im-
portant to note that minimal inhibitory concentration 
(MIC) values can also influence the therapy. The identi-
fication of the candida species may take several days after 
the detection of positive results, however it can be accel-
erated by some special techniques such as the PNA-FISH 
(Peptide Nucleic Acid Fluorescence In Situ Hybridiza-
tion) and MALDI-TOF MS (Matrix Assisted Laser De-
sorption Ionization Time-of-Flight Mass Spectrometry). 
Following blood culture positivity with the PNA-FISH 
technique, the five most common candida species can be 
identified in ninty minutes by colour coding, which can 
also help in choosing the right antifungal agent (Candida 
albicans and parapsilosis are coloured in green, Candida 
tropicalis in yellow, Candida glabrata and krusei in red) 
[51]. MALDI-TOF MS is a rapid, accurate and low-cost 
method for identification and characterization of micro-
organisms. This technology can help to create large spec-
trum of “fingerprints” which is specific and unique for 
each micro-organism. The method is perfectly applicable 
for the identification of the microbes’ genus and species 
levels and also very useful for characterization of fungi 
[52]. Samples other than blood can also be used for iden-
tification of pathogens with MALDI-TOF MS.
 Therapeutic strategies in the treat-
ment of invasive Candidiasis
The timing of antifungal therapy in invasive candidiasis 
is a major factor in terms of outcome. Several studies 
have proved that a delayed therapy has a negative ef-
fect on survival [5, 53-56]. When to commence therapy 
is closely related to the diagnostic steps and associated 
possibilities. Four strategies, prophylaxis, pre-emtive, 
empirical and targeted therapy are outlined.
Prophilaxis
The aim of prophylactic antifungal therapy is prevent-
ing infection in those who are at high-risk of devel-
oping an invasive candida infection. For prophylactic 
therapy fluconazole is used in general but recently 
echinocandins have also been successfully used [57]. 
Although the use of prophylaxis is well defined among 
transplanted and haematological patients [3], it is sel-
dom recommended for use in ICU patients [3, 21]. Of 
course there are certain situations where some groups 
of patients may benefit from prophylactic treatment 
[3,58] but further studies are needed to clarify this as-
pect. The current European recommendations for non-
neutropenic patients are summarized in Table 5 [3].
Pre-emptive therapy
According to the ESCMID definition [3], pre-emptive 
therapy means that there is microbiological evidence of 
invasive candidasis but the clinical signs of fungal infec-
tion are missing. Usually these infections belong to the 
“possible” or “probable” categories. The microbiological 
evidence is based on the 1-3 beta-D-glucan biomarker, 
mannan-antimannan double test or detection of fungal 
nucleic acid by the PCR test. In addition to the biomark-
ers, the patients’ risk factors also need to be assessed and 
various score systems must be taken into consideration 
when starting such therapy. The current European rec-
ommendations for pre-emptive antifungal therapy in 
non-neutropenic patients is given in Table 6 [3].
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Empirical therapy
According to the ESCMID definition [3], empirical, fe-
ver driven, therapy is when the patient is at-risk of fun-
gal infections with persistent fever but has no microbi-
ological evidence of invasive candidiasis, supported by 
increased risk scores. Current European recommenda-
tions for empirical antifungal therapy in non-neutro-
penic patients are summarized in Table 6 [3].
Targeted therapy
When the sensitivity to different anticandida agents 
and the MIC (minimal inhibitory concentration) of the 
Candida species grown from blood culture or other 
specimen is known, the treatment can be adapted in 
order to achieve superior results and targeted therapy.
 Choice of the antifungal agent and 
length of therapy
The antifungal agents administered to patients are af-
fected by several factors and circumstances. On the one 
hand there are a number of national and international 
guidelines which can help in choosing the appropriate 
agents. However these guidelines cannot be applied for 
all clinical scenarios. There are several factors affecting 
when and what species can be responsible for the inva-
sive candida infection in a particular patient [13,14]. 
On the other hand, we need to consider local epide-
miology and resistance profiles. The  antifungal drug’s 
spectrum for drugs are given in Table 7.
In addition we should also be aware on the MIC val-
ues (this E-testing can be only carried out in case of 
Table 5 ESCMID recommendation for antifungal prophylaxis in adult non-neutropenic patients [3]
Population Intention Intervention SoR QoE
Recent abdominal surgery AND recurrent-
gastrointestinal perforations or anastomotic 
leakages
To prevent intra-abdom-
inal Candida infection
Fluconazole 400 mg/day
Caspofungin 0/50 mg/day
B
C
I
II
Critically ill surgical patients with an expected 
length of ICU stay ‡3 day
To delay the time to 
fungal infection
Fluconazole  400 mg/day C II
Ventilated for 48 h and expected to beventi-
lated for another ‡72 h
To prevent invasive can-
didiasis/candidaemia
Fluconazole 100 mg/day C I
Ventilated, hospitalized for ‡3 day, received 
antibiotics, CVC, and ‡1 of: parenteral nutrition, 
dialysis, major surgery, pancreatitis, systemic 
steroids, immunosuppression
To prevent invasive can-
didiasis/candidaemia
Caspofungin 50 mg/day C II
Surgical ICU patients To prevent invasive can-
didiasis/candidaemia
Ketoconazole 200 mg/day D I
Critically ill patients with risk factors for invasive 
candidiasis/candidaemia
To prevent invasive can-
didiasis/candidaemia
Itraconazole  400 mg/day D I
Surgical ICU with catabolism To prevent invasive can-
didiasis/candidaemia
Nystatin 4 Mio IU/day D I
SoR: Strength of recommendation, QoE: Quality of evidence, ICU: intensive care unit, CVC: central venous catheter, IU: international units.
Table 6. ESCMID recommendation for pre-emptive and empirical therapy in adult non-neutropenic patients [3]
Population Intention Intervention SoR QoE
Adult ICU patients with fever despite broad-
spectrum antibiotics and APACHEII >16
To resolve fever Fluconazole 800 
mg/day
D I
ICU patients persistently febrile, but without-
microbiological evidence To reduce overall mortality
Fluconazole or 
echinocandin C II
ICU patients with candida isolated from respi-
ratory secretions
To cure invasive candidiasis 
or candidaemia early Any antifungal D II
ICU patients with positive (1,3)-b-D-glucantest
To cure invasive candidiasis 
or candidaemia early Any antifungal C II
Any patient with Candida isolated from a blood 
culture To cure invasive candidiasis
Antifungal treat-
ment A II
SoR: Strength of recommendation, QoE: Quality of evidence, APACHE: acute physiology and chronic health evaluation
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fully known species of Candida). The sensibility degree 
to the antifungal agent, expressed in points, can be in-
terpreted in accordance with the EUCAST (European 
Committee on Antimicrobial Susceptibility Testing) or 
CLSI (Clinical and Laboratory Standards Institute) da-
tabase.
The current European recommendations for anti-
fungal therapy in non-neutropenic adult patients is 
given in Table 8 [3].
The duration of the therapy is influenced by many 
factors and current recommendations are mainly based 
on consensus rather than clear evidence. Basically, in 
case of  a positive blood culture for a candida spe-
cies, empiric antifungal therapy should be started im-
mediately followed by obtaining daily blood cultures. 
According to current recommendations, the patient 
should be treated for a minimum of fourteen addition-
al days after the first negative culture results have been 
recorded. De-escalation is also possible or a switch to 
oral therapy after ten days, after  taking into account 
the existing clinical picture [3]. In cases of deep-seat-
ed candidiasis, the therapy should be continued for a 
longer period. In these cases the clinical picture and the 
source of infection determine the choice of the antifun-
gal agent and the length of therapy. If candidaemia is 
present, ophthalmological examination and transtho-
racic or transesophageal echocardiography is man-
datory in all cases to exclude intraocular candidiasis 
and infective endocarditis. The infected intravascular 
catheters must be removed as soon as possible. If this 
Table 7. Antifungal activity spectrum and Candida species [59]
Candida spp. AMB FLU ITRA VOR POSA CAS MIC ANI
C.albicans ++ ++ ++ ++ ++ ++ ++ ++
C.glabrata + +/- +/- + + ++ ++ ++
C.parapsilosis ++ ++ ++ ++ ++ + + +
C.tropicalis ++ ++ ++ ++ ++ ++ ++ ++
C.krusei + - +/- + + ++ ++ ++
C.rugosa + + + ++ ++ + + +
C.guilliermondii ++ ++ ++ ++ ++ + + +
C.lusitaniae ++ ++ ++ ++ ++ ++ ++ ++
C.inconspicua ++ - + + + ++ ++ ++
C.norvegensis ++ - +/- +/- +/- ++ ++ ++
In vitro inherentactivity: ++good activity, +mild activity, +/- slight activity,- no activity. AMB amphotericin B, FLU fluconazole, ITRA itraconazole, VOR voriconazole, POSA posaconazole, CAS caspofungin, MIC 
micafungin, ANI anidulafungin
Table 8. ESCMID recommendation for antifungal therapy [3]
Intervention SoR QoE Comment
Anidulafungin 200/100 mg A I Consider local epidemiology (Candida parapsilosis, Candida 
krusei), less drug–drug interactions than caspofungin
Caspofungin 70/50 mg A I Consider local epidemiology (C. parapsilosis)
Micafungin 100 mg A I Consider local epidemiology (C. parapsilosis), less drug–drug 
interactions than caspofungin,
Amphotericin B liposomal 3 mg/kg B I Similar efficacy as micafungin, higher renal toxicity than mica-fungin
Voriconazole 6/3 mg/kg/day B I
Limited spectrum compared to echinocandins, drug–drug 
interactions, limitation of IV formulation in renal impairment, 
consider therapeutic drug monitoring
Fluconazole 400–800 mg C I
Limited spectrum, inferiority to anidulafungin (especially in the 
subgroupwith high APACHE scores), may be better than echino-
candins against C. parapsilosis
Amphotericin B lipid complex 5 mg/kg C II -
Amphotericin B deoxycholate 0.7–1.0 
mg/kg
D I Substantial renal and infusion-related toxicity
SoR: Strength of recommendation, QoE: Quality of evidence
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is not possible then echinocandin, liposomal or lipid 
complex amphotericin-B must be started because they 
are also able to diffuse into the biofilm [3].
 Summary
The increasing number of invasive fungal infections are 
a real and important problem in critically ill patients. 
Although significant progress has been made in both 
the diagnostics and therapy over the last years, inva-
sive fungal infections are still often overlooked. Early 
diagnosis and antifungal therapy without delay are the 
only chances that can improve the chances for survival 
of these patients. According to our present knowledge 
the preemptive therapy may be the most promising 
approach. Applying biomarkers and fungal DNA tests 
can improve diagnostic accuracy and makes early treat-
ment possible. Nevertheless, there are several issues 
to be solved in the future including both diagnostics, 
therapy and determination of the length of treatment.
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